Payment overview · 2025
General Payments
$207.47
11 reported records · 7 companies
Healthcare provider profile · identity verified
Whitney Mcclintock, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DOVER, OH · NPI 1003481177
Verified facts
What the public records show
CMS Open Payments records show Whitney Mcclintock, APRN received $207.47 in general payments during 2025 across 11 reported records.
Astellas Pharma US Inc accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.73 | 29.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.25 | 17.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.18 | 16.5% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.70 | 10.0% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $20.50 | 9.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.36 | 9.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.75 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.47 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $60.73 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 115 |
| Losartan Potassium | Losartan Potassium | 233 | 86 |
| Lisinopril | Lisinopril | 227 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 220 | 96 |
| Omeprazole | Omeprazole | 182 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 59 |
| Metformin Hcl | Metformin Hcl | 105 | 36 |
| Gabapentin | Gabapentin | 98 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 33 |
| Sertraline Hcl | Sertraline Hcl | 89 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 26 |
| Eliquis | Apixaban | 82 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 31 |
| Furosemide | Furosemide | 73 | 41 |
| Potassium Chloride | Potassium Chloride | 73 | 25 |
| Famotidine | Famotidine | 70 | 26 |
| Metformin Hcl Er | Metformin Hcl | 66 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 42 |
| Ozempic | Semaglutide | 62 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 20 |
| Trazodone Hcl | Trazodone Hcl | 55 | 19 |
| Simvastatin | Simvastatin | 53 | 20 |
| Prednisone | Prednisone | 49 | 42 |
| Alprazolam | Alprazolam | 48 | 26 |
| Glipizide Er | Glipizide | 48 | 23 |
| Warfarin Sodium | Warfarin Sodium | 46 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 18 |
| Pregabalin | Pregabalin | 44 | 11 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Meloxicam | Meloxicam | 41 | 19 |
| Jardiance | Empagliflozin | 40 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 16 |
| Alendronate Sodium | Alendronate Sodium | 36 | 14 |
| Synthroid | Levothyroxine Sodium | 36 | 16 |
| Carvedilol | Carvedilol | 35 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 33 |
| Montelukast Sodium | Montelukast Sodium | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 11 |
| Tramadol Hcl | Tramadol Hcl | 35 | 15 |
| Allopurinol | Allopurinol | 34 | 18 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Ezetimibe | Ezetimibe | 28 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 22 |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.47 · 11 records | Astellas Pharma US Inc | Azstarys, CAPLYTA, LOREEV XR, MOUNJARO, VRAYLAR, Veozah, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error